Tumor mutational load predicts survival after immunotherapy across multiple cancer types
-
Published:2019-01-14
Issue:2
Volume:51
Page:202-206
-
ISSN:1061-4036
-
Container-title:Nature Genetics
-
language:en
-
Short-container-title:Nat Genet
Author:
Samstein Robert M.ORCID, Lee Chung-Han, Shoushtari Alexander N.ORCID, Hellmann Matthew D.ORCID, Shen Ronglai, Janjigian Yelena Y., Barron David A., Zehir AhmetORCID, Jordan Emmet J., Omuro Antonio, Kaley Thomas J., Kendall Sviatoslav M., Motzer Robert J.ORCID, Hakimi A. Ari, Voss Martin H., Russo Paul, Rosenberg Jonathan, Iyer GopaORCID, Bochner Bernard H., Bajorin Dean F., Al-Ahmadie Hikmat A., Chaft Jamie E., Rudin Charles M.ORCID, Riely Gregory J., Baxi Shrujal, Ho Alan L., Wong Richard J., Pfister David G., Wolchok Jedd D., Barker Christopher A., Gutin Philip H., Brennan Cameron W., Tabar Viviane, Mellinghoff Ingo K., DeAngelis Lisa M., Ariyan Charlotte E., Lee Nancy, Tap William D., Gounder Mrinal M., D’Angelo Sandra P., Saltz Leonard, Stadler Zsofia K., Scher Howard I., Baselga Jose, Razavi Pedram, Klebanoff Christopher A., Yaeger Rona, Segal Neil H., Ku Geoffrey Y., DeMatteo Ronald P., Ladanyi Marc, Rizvi Naiyer A., Berger Michael F., Riaz Nadeem, Solit David B.ORCID, Chan Timothy A.ORCID, Morris Luc G. T.ORCID
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Callahan, M. K., Postow, M. A. & Wolchok, J. D. Targeting T cell co-receptors for cancer therapy. Immunity 44, 1069–1078 (2016). 2. Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018). 3. Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017). 4. Cohen, E. E. et al. LBA45_PR Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. Ann. Oncol. 28, mdx440.040 (2017). 5. Bendell, J. et al. LBA-004 Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab + cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann. Oncol. 29, mdy208.003 (2018).
Cited by
2852 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|